What condition is Revcovi used to treat?

Revcovi is used to treat adenosine deaminase severe combined immune deficiency, an inherited disorder where patients lack immune protection from bacteria, viruses, and fungi.

In October 2018, the U.S. Food and Drug Administration (FDA) granted approval to Revcovi (elapegademase-lvlr) injection from Leadiant Biosciences. Revcovi is an intramuscular (IM) enzyme replacement therapy for treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in children and adults.

• ADA-SCID is a fatal inherited genetic disorder and primarily affects infants and young children. Undiagnosed babies with ADA-SCID usually die before age two due to infections.
• In two multicenter trials, Revcovi supplemented ADA levels, reduced concentrations of toxic metabolites, and improved total lymphocyte counts.
• The most commonly reported side effects were cough and vomiting.

See also:

Drug information

• Revcovi
• Elapegademase

Related support groups

• Revcovi (1 questions, 3 members)
• Elapegademase (1 questions, 3 members)
• Adenosine Deaminase Deficiency (1 questions, 3 members)

Medical Disclaimer